Complete Infectious Disease Bootcamp Syllabus — 14 clinical topics, reorganized so the six core PANCE ID topics come first. Now expanded with Module D: Must-Know Differentials (7 high-yield diagnostic frameworks) and Module E: Board Pearls (domain-organized clinical decision points). Board questions available in the companion document.
| CD4 Threshold | OI | Prophylaxis | Board Key |
|---|---|---|---|
| <200 | PCP (Pneumocystis jirovecii) | TMP-SMX DS daily — FIRST-LINE | Most important OI prophylaxis drug |
| <100 | Toxoplasma (if seropositive) | TMP-SMX DS daily — covers BOTH PCP AND Toxo | One drug = two OIs covered |
| <100 | Cryptococcus (if CrAg+) | Fluconazole 200mg daily | Screen with serum CrAg in high-prevalence areas |
| <150 (endemic) | Histoplasmosis | Itraconazole 200mg daily | Ohio/Mississippi valleys only |
| Any CD4 | LTBI | INH × 9mo or rifampin × 4mo + pyridoxine | Screen all HIV patients with TST/IGRA |
| Any CD4 | MAC | NO LONGER routinely recommended if ART started immediately (2024 update) | Major guideline change |
| OI | CD4 | Classic Presentation | Key Dx | Treatment |
|---|---|---|---|---|
| PCP | <200 | Bilateral diffuse GGO on CT; elevated LDH; hypoxia worsens with exertion; dry cough; CXR may be NORMAL early | Sputum or BAL silver stain/DFA | TMP-SMX high dose × 21d. Add prednisone if PaO₂ <70 or A-a gradient >35. |
| Toxoplasmosis | <100 | Multiple ring-enhancing lesions on MRI; headache; focal deficits | MRI + toxo serology. Empiric treatment. | Pyrimethamine + sulfadiazine + leucovorin |
| Crypto meningitis | <100 | Headache, fever, elevated opening pressure on LP; India ink positive | ALWAYS measure opening pressure. CrAg serum + CSF. | Amphotericin B + flucytosine (induction × 2wk) → fluconazole maintenance |
| CMV retinitis | <50 | "Pizza pie" fundoscopy (hemorrhages + exudates). Vision loss. | Ophthalmologic exam | Valganciclovir PO or ganciclovir IV |
| MAC | <50 | Fever, night sweats, weight loss, diarrhea, elevated alk phos | Mycobacterial blood cultures | Azithromycin + ethambutol |
| CNS Lymphoma | <50 | SINGLE ring-enhancing lesion; EBV-associated | CSF EBV DNA; biopsy if no toxo response | Radiation ± chemo; poor prognosis |
This topic is free — a real look at how we teach. The remaining 17 topics below, along with interactive diagrams, EKG popups, Module D differentials, Module E board pearls, and audio mnemonics, are included with bootcamp enrollment.
The 2025 IDSA guidelines changed how UTI is classified. Diabetes, immunocompromise, and benign prostatic hyperplasia alone do NOT make a UTI "complicated" if the infection appears confined to the bladder — both men and women can now have uncomplicated UTI.
🚨 Classic Trap: A diabetic woman with isolated dysuria and no systemic signs has UNCOMPLICATED cystitis under the 2025 reclassification — don't reflexively label her "complicated" based on her diabetes alone.
| Organism | Frequency | Key Notes |
|---|---|---|
| E. coli | 75–90% | Most common cause of both uncomplicated and complicated UTI |
| Klebsiella pneumoniae | 6–8% | Second most common Gram-negative |
| S. saprophyticus | 5–6% | #2 cause in young sexually active women — classic board question |
| Proteus mirabilis | 2–5% | Urease-producing → alkaline urine → struvite (staghorn) stones |
| Enterococcus | ~5% | Intrinsically resistant to cephalosporins |
| Pseudomonas | <5% | More common in catheterized/healthcare-associated UTI |
🩺 PANCE Pearl: S. saprophyticus is coagulase-negative and novobiocin-RESISTANT — this distinguishes it from S. epidermidis, which is novobiocin-sensitive. A classic board differentiator.
| Cystitis | Pyelonephritis | |
|---|---|---|
| Symptoms | Dysuria, frequency, urgency, suprapubic pain. NO fever. | Cystitis symptoms + fever, rigors, CVA tenderness, N/V |
| Culture required? | NOT mandatory in non-pregnant women with typical symptoms | ALWAYS obtain — confirmatory test is ≥10,000 CFU/mL of a uropathogen |
| First-line Rx | Nitrofurantoin, TMP-SMX, fosfomycin, or pivmecillinam | Fluoroquinolone (outpatient) or IV ceftriaxone/cefepime/pip-tazo (inpatient) |
| Nitrofurantoin OK? | YES — high urine concentration | NO — inadequate renal tissue levels |
🩺 PANCE Pearl: Urine culture is recommended for recurrent UTI, treatment failure, atypical presentation, men, and age ≥65 — even in suspected cystitis.
🚨 Classic Trap: Sterile pyuria differential — TB of the urinary tract, interstitial nephritis, nephrolithiasis, urethritis (Chlamydia), recently treated UTI, bladder cancer. Don't assume "no growth + WBCs" means lab error.
Uncomplicated pyelonephritis responding to therapy does NOT need imaging. Order CT abdomen/pelvis only for:
CT with contrast detects abscess/gas; CT without contrast detects stones; ultrasound is preferred in pregnancy and is more sensitive for hydronephrosis.
🚨 Classic Trap: Do NOT order imaging for uncomplicated pyelonephritis that is improving on therapy — this is a frequently tested unnecessary-testing trap.
| Agent | Dose | Duration | Key Notes |
|---|---|---|---|
| Nitrofurantoin | 100mg BID | 5 days | Take with food; avoid if CrCl <30 (label says <60); NEVER for pyelonephritis |
| TMP-SMX | 160/800mg BID | 3 days | Only if local resistance <20%; avoid if recent use |
| Fosfomycin | 3g | 1 dose | Convenient but may be less effective than multi-day regimens |
| Pivmecillinam | 400mg TID | 3 days | Recently FDA-approved in the US for uncomplicated UTI in women |
🚨 Classic Trap: Do NOT use amoxicillin or ampicillin empirically — E. coli resistance rates exceed 40%. Fluoroquinolones are NOT first-line for uncomplicated cystitis (reserved for pyelonephritis/invasive infection).
🚨 Classic Trap: TMP-SMX should NOT be used empirically for pyelonephritis — resistance rates approach 20% in many US regions. Use only after susceptibility is confirmed.
| Syndrome | Duration |
|---|---|
| Uncomplicated cystitis (women) | 3–5 days (agent-dependent) |
| Uncomplicated cystitis (men) | 7 days |
| Pyelonephritis (fluoroquinolone) | 5–7 days |
| Pyelonephritis (non-fluoroquinolone) | 7 days |
| Gram-negative bacteremia, urinary source | 7 days if afebrile/stable/source controlled |
| CAUTI | 7 days (up to 10–14 if slow response) |
🩺 PANCE Pearl: Shorter courses (5–7 days) are as effective as longer courses (10–14 days) per meta-analysis — this is a major 2025 update. Men with complicated UTI may still benefit from 10–14 days given occult prostatitis risk.
🚨 Classic Trap: Treating ASB in the elderly does NOT reduce mortality, does NOT prevent symptomatic UTI, and INCREASES C. diff risk and antimicrobial resistance. Delirium alone in an elderly patient with bacteriuria should prompt evaluation for OTHER causes of delirium — not reflexive antibiotics.
Defined as ≥3 UTIs/year or ≥2 in 6 months. Evidence-based preventive measures:
🩺 PANCE Pearl: "Honeymoon cystitis" — UTI associated with intercourse — responds well to post-coital prophylaxis with a single dose of TMP-SMX or nitrofurantoin.
| STI | First-Line Treatment | Key Change / Board Trap |
|---|---|---|
| Chlamydia | Doxycycline 100mg BID × 7 days | Doxy NOW PREFERRED over azithromycin — better efficacy, especially rectal chlamydia |
| Gonorrhea | Ceftriaxone 500mg IM × 1 (1g if ≥150kg) | Azithromycin co-treatment NO LONGER recommended — ceftriaxone MONOTHERAPY |
| Syphilis — Primary/Secondary/Early Latent | Benzathine penicillin G 2.4 MU IM × 1 | Penicillin ONLY in pregnancy — if allergic, desensitize |
| Syphilis — Late Latent/Unknown Duration | Benzathine penicillin G 2.4 MU IM weekly × 3 (total 7.2 MU) | 3 weekly doses |
| Neurosyphilis | IV aqueous crystalline penicillin G × 10–14 days | Can occur at ANY stage — evaluate for ocular/otic/neuro symptoms in all syphilis |
| PID | Ceftriaxone 500mg IM + doxycycline × 14d + metronidazole × 14d | Metro NOW routinely added for anaerobic coverage (2021 update) |
| Trichomoniasis | Women: Metro 500mg BID × 7d | Men: 2g × 1 | 7-day course preferred for women |
| Genital herpes (1st episode) | Acyclovir 400mg TID × 7–10d | Valacyclovir 1g BID is an alternative |
| Test Type | Tests | Use | Board Key |
|---|---|---|---|
| Non-treponemal (quantitative) | RPR, VDRL | Screening + monitoring treatment response (titers fall with effective treatment) | Can be false-positive: pregnancy, lupus, viral infections |
| Treponemal (confirmatory) | FTA-ABS, TP-PA | Confirmatory. Remain POSITIVE FOR LIFE even after cure. | Do NOT use to monitor treatment response — positive forever |
| Positive if | Who | Board Key |
|---|---|---|
| ≥ 5 mm | HIV infection · recent close contact of an active case · fibrotic changes on CXR consistent with prior TB · organ transplant recipients · immunosuppression (prednisone ≥15 mg/day for ≥1 month, TNF-α inhibitors) | The most immunosuppressed get the smallest cutoff — they mount the weakest reaction |
| ≥ 10 mm | Health care workers · residents and employees of prisons, homeless shelters, nursing homes · recent immigrants (<5 years) from high-prevalence countries · injection drug users · mycobacteriology lab personnel · children <5 years · diabetes, ESRD, silicosis, leukemia/lymphoma, gastrectomy | The single most tested cutoff — a hospital employee with 12 mm is POSITIVE |
| ≥ 15 mm | Persons with no identified risk factors | Applying this number to a higher-risk patient is the classic error |
| TST (PPD) | IGRA (QuantiFERON-TB Gold Plus, T-SPOT.TB) | |
|---|---|---|
| Method | Intradermal injection, return visit to read | Single blood draw, no return visit |
| BCG cross-reaction | Yes — can cause false positives | No — preferred in BCG-vaccinated patients |
| Preferred when | Children <5 years; serial screening programs where two-step testing is established | BCG history; patients unlikely to return for a reading |
| Critical limitation | NEITHER test distinguishes latent infection from active disease, and neither one rules active TB out. Interpretation always requires chest imaging plus a symptom screen. | |
| Latent TB Infection (LTBI) | Active TB Disease | |
|---|---|---|
| Symptoms | None | Cough >2–3 weeks, fever, night sweats, weight loss, hemoptysis |
| Chest X-ray | Normal (or old, stable fibrotic scarring) | Upper lobe infiltrate with cavitation; hilar adenopathy. In advanced HIV the film may be atypical — lower lobe, miliary, or normal |
| Diagnosis | Positive TST or IGRA + normal CXR + asymptomatic | Sputum ×3 for AFB smear and mycobacterial culture, plus NAAT on at least one specimen for rapid confirmation. Culture remains the gold standard and gives susceptibilities |
| Infectious? | No | Yes — airborne (negative-pressure) isolation, N95 for staff |
| Reporting | Varies by jurisdiction; several states now require LTBI reporting | Active TB is a nationally notifiable disease — report to the local health department. The department performs contact investigation and can supervise directly observed therapy |
| Drug | Signature Toxicity | Monitoring / Action |
|---|---|---|
| Rifampin | Orange-red urine, sweat, and tears (harmless; permanently stains soft contact lenses). Potent CYP450 INDUCER. Hepatotoxicity, thrombocytopenia, flu-like syndrome | Oral contraceptives fail — advise a backup method. Warfarin, methadone, and many antiretrovirals drop; consider rifabutin |
| Isoniazid | Peripheral neuropathy · hepatotoxicity · drug-induced lupus · sideroblastic anemia. Unlike rifampin, INH is a CYP inhibitor | Give pyridoxine (B6) to prevent neuropathy. Baseline LFTs; recheck with symptoms |
| Pyrazinamide | Hyperuricemia → gout flare · arthralgias · hepatotoxicity | Check uric acid if joint pain develops. Stops at 2 months |
| Ethambutol | Optic neuritis — decreased visual acuity + loss of red-green color discrimination. Dose-dependent; usually reversible if caught early | Baseline and monthly visual acuity and color vision testing. Any visual change → stop the drug and refer |
Definite IE: 2 Major OR 1 Major + 3 Minor OR 5 Minor criteria
Major Criteria:
Minor Criteria:
🩺 PANCE Pearl: Osler nodes = painful (immune complex) · Janeway lesions = painless (septic emboli). "Osler HURTS, Janeway DOESN'T." Both are peripheral signs of IE.
| Organism | Classic Association | Board Key |
|---|---|---|
| S. aureus | IVDU (tricuspid), acute IE, prosthetic valves | #1 cause overall. IVDU → right-sided tricuspid valve. High mortality. |
| Viridans streptococci | Native valve subacute, dental procedures | Subacute course. Penicillin-susceptible. |
| S. bovis/gallolyticus | Colon lesions, elderly | MANDATORY colonoscopy — ~60% colorectal neoplasia association |
| Enterococcus | GI/GU procedures | Synergistic therapy: ampicillin + gentamicin OR ampicillin + ceftriaxone |
| HACEK organisms | Culture-negative IE (slow-growing gram-negatives) | Treat with ceftriaxone. Prolonged incubation needed for cultures. |
| S. epidermidis (CoNS) | Prosthetic valve <60 days | Early prosthetic (<60d) = CoNS. Late (>60d) = same as native valve. |
| Finding | Pain? | Mechanism | Location |
|---|---|---|---|
| Osler nodes | PAINFUL — "Ouch-sler" | Immune complex deposition | Finger/toe pulp |
| Janeway lesions | PAINLESS | Septic microemboli | Palms and soles |
| Roth spots | — | Retinal hemorrhages with white center | Fundoscopic exam |
| Splinter hemorrhages | — | Septic microemboli in nail capillaries | Subungual |
| Age Group | Key Organisms | Empiric Therapy | Board Key |
|---|---|---|---|
| Neonates (0–28d) | Group B Strep, E. coli, Listeria | Ampicillin + cefotaxime (or gentamicin) | GBS #1 neonates |
| Children/Adults (1mo–50yr) | S. pneumoniae (#1), N. meningitidis | Vancomycin + ceftriaxone | Vanco covers pen-resistant pneumococcus |
| Adults >50 / Immunocompromised / Pregnant | S. pneumoniae, N. meningitidis, Listeria | Vancomycin + ceftriaxone + AMPICILLIN | Cephalosporins have ZERO Listeria coverage — ampicillin is essential |
| Parameter | Bacterial | Viral (Aseptic) | Fungal/TB |
|---|---|---|---|
| Opening Pressure | Elevated (>20 cm H₂O) | Normal or mildly elevated | Elevated |
| WBC / Cell type | >1000, neutrophil predominant | 10–500, lymphocyte predominant | 10–500, lymphocyte |
| Glucose | LOW (<40 mg/dL) | Normal | LOW |
| Protein | HIGH (>250 mg/dL) | Normal/mildly elevated | HIGH |
Sepsis is the #1 cause of ICU mortality in the US. Boards test: Sepsis-3 definition (SOFA-based, NOT SIRS), vasopressor selection, the Hour-1 Bundle, and fluid strategy. Multiple questions per exam.
| Line | Agent | Notes | Board Key |
|---|---|---|---|
| First-line | Norepinephrine | Titrate to MAP ≥65 | NOT dopamine — higher arrhythmia risk with dopamine |
| Second-line | Vasopressin 0.03 units/min | Add when NE ≥0.25–0.5 mcg/kg/min | NE-sparing; fixed dose |
| Third-line | Epinephrine | Refractory shock | Can cause lactic acidosis (β2) |
| Adjunct | Hydrocortisone 200 mg/day CI | Vasopressor-refractory septic shock | Weak recommendation; improves shock reversal |
| Setting | First-Line | Alternative | Board Key |
|---|---|---|---|
| Outpatient, no comorbidities | Amoxicillin 1g TID OR doxycycline 100mg BID | Macrolide if local resistance <25% | Macrolide monotherapy NOT recommended (resistance >30%) |
| Outpatient, with comorbidities | Amox-clav + macrolide or doxy | Respiratory FQ (levofloxacin) | FQ only if β-lactam/macrolide not tolerated |
| Inpatient, nonsevere | Ceftriaxone + azithromycin | Respiratory FQ monotherapy | Combination preferred |
| Inpatient, severe/ICU | β-lactam + macrolide or β-lactam + FQ | + anti-MRSA/pseudomonal only if risk factors | Hydrocortisone 200mg/day IV for severe CAP reduces mortality (CAPE COD trial) |
Duration: 3 days if stability criteria met by day 3. 5 days if met by day 5. ≥7 days for MRSA or Pseudomonas.
| Episode/Severity | Definition | Treatment |
|---|---|---|
| Initial, Nonsevere | WBC ≤15K, Cr <1.5 | Vancomycin 125mg PO QID × 10d OR Fidaxomicin 200mg BID × 10d |
| Initial, Severe | WBC >15K or Cr ≥1.5 | Vancomycin 125mg PO QID × 10d OR Fidaxomicin 200mg BID × 10d |
| Fulminant | Hypotension, ileus, toxic megacolon | Vancomycin 500mg PO QID + Metronidazole 500mg IV TID ± Vancomycin per rectum (if ileus) |
| 1st Recurrence | — | Vancomycin taper/pulse OR Fidaxomicin (preferred — fewer recurrences) |
| 2nd+ Recurrence | — | FMT — >85% cure rate. FDA-approved: Rebyota (fecal), Vowst (oral spores) |
| Type | Organism | Treatment | Board Key |
|---|---|---|---|
| Mild nonpurulent cellulitis | β-hemolytic Streptococcus (NOT MRSA) | Oral cephalexin or dicloxacillin × 5 days | Routine MRSA coverage NOT needed |
| Moderate cellulitis | β-hemolytic Strep | IV cefazolin or ceftriaxone | Upgrade if 1–2 SIRS criteria |
| Severe cellulitis | Mixed, MRSA possible | IV vancomycin + pip-tazo. Surgical consult if necrotizing features. | SIRS + hypotension/sepsis |
| Purulent SSTI (abscess) | S. aureus / MRSA | I&D is PRIMARY treatment. Add TMP-SMX/doxy only if surrounding cellulitis or SIRS. | Antibiotics alone = insufficient |
| Erysipelas | Group A Strep | Penicillin VK or amoxicillin (IV PCN G if severe) | Sharply demarcated, raised, bright red borders |
| Stage | Timing | Key Manifestations | Treatment |
|---|---|---|---|
| Stage 1 — Early Localized | Days–weeks after bite | Erythema migrans (EM): Bull's-eye rash ≥5cm, expanding annular erythema with central clearing. Pathognomonic — no serology needed in endemic area. ± fever, fatigue, myalgias. | Doxycycline 100mg BID × 10–21d (adults). Amoxicillin 500mg TID × 14–21d (pregnancy, children <8yr). |
| Stage 2 — Early Disseminated | Weeks–months | Cardiac: AV block (1st, 2nd, 3rd degree; PR prolongation is hallmark). Neuro: Facial nerve palsy (BILATERAL = Lyme until proven otherwise), meningitis, radiculopathy. Multiple EM lesions. | Oral doxy for uncomplicated. IV ceftriaxone 2g daily × 14–28d for complete heart block, meningitis, neurologic Lyme. |
| Stage 3 — Late Disseminated | Months–years | Lyme arthritis: Intermittent/persistent monoarthritis or oligoarthritis; KNEE most common. "Hot swollen knee" in endemic area = Lyme. Neurologic: Encephalopathy, peripheral neuropathy. | Doxycycline 100mg BID × 28d (arthritis). IV ceftriaxone for severe neurologic Lyme. Refractory arthritis → anti-inflammatory or DMARD. |
| Drug | Route/Duration | Board Key |
|---|---|---|
| Oseltamivir (Tamiflu) | 75mg BID × 5 days PO | First-line for most patients. Safe in pregnancy. Adjust for renal impairment. |
| Zanamivir (Relenza) | 2 inhalations BID × 5 days (inhaled) | CONTRAINDICATED in asthma/COPD — risk of severe bronchospasm |
| Baloxavir marboxil (Xofluza) | Single oral dose (weight-based) | Alternative for uncomplicated flu in low-risk outpatients |
| IV peramivir | 600mg IV × 1 dose | For hospitalized patients who cannot take oral/inhaled medications |
| Drug | Mechanism/Duration | Board Key |
|---|---|---|
| Nirmatrelvir/ritonavir (Paxlovid) | Protease inhibitor + CYP3A4 inhibitor booster. 5 days PO. Start within 5 days of onset. | Multiple CYP3A4 drug interactions via ritonavir. ~85% reduction in hospitalization/death in high-risk. |
| Remdesivir | RNA polymerase inhibitor. 3 days IV (outpatient) or 5 days IV (hospitalized non-ventilated) | 3-day IV course for high-risk outpatients who cannot take oral medications |
| Molnupiravir | RNA polymerase inhibitor (mutagenic). 5 days PO. | Less effective than Paxlovid. CONTRAINDICATED in pregnancy — mutagenic potential. |
| Dexamethasone 6mg/day × ≤10d | Anti-inflammatory | ONLY for hospitalized patients requiring O₂ or ventilatory support (RECOVERY trial). AVOID in non-O₂-requiring outpatients. |
Ritonavir is a potent CYP3A4 inhibitor — dramatically increases levels of co-administered drugs:
| Drug Category | Examples | Action Required |
|---|---|---|
| CYP3A4-metabolized statins | Atorvastatin, simvastatin, lovastatin | HOLD during Paxlovid course — risk of myopathy/rhabdomyolysis. OK: rosuvastatin, pravastatin. |
| DOACs | Rivaroxaban, apixaban, warfarin | Dose adjustment or hold. Increase INR monitoring for warfarin. |
| Immunosuppressants | Tacrolimus, cyclosporine, sirolimus | Dramatic level increase → toxicity. Urgent dose reduction + level monitoring. |
| CYP3A4 inducers (reduce Paxlovid efficacy) | Carbamazepine, phenytoin, phenobarbital, rifampin | These LOWER Paxlovid levels → choose alternative antiviral |
| Cardiac drugs | Amiodarone, dronedarone, ranolazine | Avoid — risk of serious arrhythmias |
| Organism | Epidemiology | Classic Presentation | Dx | Treatment |
|---|---|---|---|---|
| Candida (mucosal) | Antibiotics, corticosteroids, DM, dentures, immunocompromised | Oral thrush: white plaques (scrape off → raw surface). Esophageal: odynophagia + dysphagia. | Clinical (oral); EGD (esophageal) | Oral: nystatin. Esophageal: fluconazole × 14–21d. |
| Invasive Candidiasis | ICU, TPN, broad-spectrum ABx, central venous catheter, abdominal surgery | Fever unresponsive to antibiotics in ICU. Can cause endophthalmitis. | Blood cultures (50% sensitive). β-D-glucan. Fundoscopic exam mandatory in ALL candidemic patients. | Echinocandin FIRST-LINE (caspofungin, micafungin). Fluconazole if stable + susceptible. Remove CVC. |
| Invasive Aspergillosis | Prolonged neutropenia, stem cell transplant, high-dose corticosteroids | Fever + non-responding pneumonia + CT "halo sign" (GGO surrounding nodule = early finding) or air-crescent sign (late) | CT chest: halo sign. BAL galactomannan. Serum galactomannan. | Voriconazole FIRST-LINE. Isavuconazole (alternative). Liposomal amphotericin B if azole-intolerant. |
| Coccidioidomycosis | Southwest US (AZ, CA, TX). Soil/dust exposure. | Primary "Valley Fever": flu-like + cough + erythema nodosum/multiforme. Disseminated (immunocompromised): meningitis, bone/joint. | Serology (IgM early, IgG late). Sputum culture. | Mild: fluconazole. Severe: amphotericin B → fluconazole. Meningitis: LIFELONG fluconazole (100% relapse if stopped). |
| Histoplasmosis | Ohio/Mississippi river valleys; bird/bat droppings; caves. CD4 <150 = prophylaxis with itraconazole. | Mimics TB. Progressive disseminated (immunocompromised): fever, weight loss, hepatosplenomegaly, oral ulcers, pancytopenia. | Urine histoplasma antigen (BEST for acute disseminated). Serology. | Mild: itraconazole. Moderate-severe: amphotericin B → itraconazole. |
| Diagnosis | Rash Character | Key Distinguishing Feature | Cannot Miss |
|---|---|---|---|
| Rocky Mountain Spotted Fever (RMSF) | Blanching macules/papules → petechiae → purpura. Starts wrists/ankles → spreads centrally (centripetal). Palms and soles involved. | Tick exposure history (Dermacentor tick). Fever + rash on palms/soles = RMSF until proven otherwise. | Start doxycycline IMMEDIATELY — do NOT wait for confirmatory testing. Delay = death. Even in children. |
| Meningococcemia (N. meningitidis) | Petechial/purpuric rash — non-blanching. Rapid spread. May progress to purpura fulminans. | Abrupt onset high fever + meningismus + non-blanching petechiae = meningococcemia. College student, complement deficiency, asplenia are risk factors. | Blood cultures + IV ceftriaxone immediately. Rifampin prophylaxis for close contacts. Waterhouse-Friderichsen = bilateral adrenal hemorrhage. |
| Viral Exanthem (measles, rubella, EBV, enterovirus) | Maculopapular, erythematous, blanching. Spreads cephalocaudally (head to toe) in measles. | Koplik spots (white dots on buccal mucosa) = measles pathognomonic. EBV: posterior cervical lymphadenopathy + splenomegaly + atypical lymphocytes. | Amoxicillin rash in EBV is maculopapular, not urticarial — does NOT mean penicillin allergy. |
| Drug-Induced Exanthem / SJS / TEN | Maculopapular → urticarial. SJS: targetoid lesions + mucosal involvement + epidermal detachment <10% BSA. TEN: >30% BSA detachment. | Onset 1–3 weeks after starting new drug (allopurinol, sulfonamides, anticonvulsants, NSAIDs). Mucosal involvement = SJS/TEN not simple drug rash. | SJS/TEN: stop the offending drug immediately. Burn unit care. Steroids controversial. Mortality in TEN up to 30%. |
| Secondary Syphilis | Copper-colored maculopapular rash — characteristically involves palms and soles. Non-pruritic. | Diffuse rash + palms/soles + lymphadenopathy + condyloma lata + 4–10 weeks after primary chancre. RPR/VDRL positive. | Secondary syphilis rash is non-pruritic — if the rash itches, reconsider. Palm/sole involvement is the classic board clue. |
| Toxic Shock Syndrome (TSS) | Diffuse sunburn-like erythroderma. Desquamation of palms/soles occurs 1–2 weeks later. | Tampon use or wound infection + fever >38.9 + hypotension + diffuse sunburn rash + multi-organ involvement. S. aureus toxin (TSST-1) mediated. | Streptococcal TSS is more severe (higher mortality ~30–60%). Source control (remove tampon, debride wound) is critical. |
| Type | Opening Pressure | WBC (cells/μL) | Predominant Cell | Glucose | Protein | Key Feature |
|---|---|---|---|---|---|---|
| Bacterial | ↑↑ (>200) | >1000 (100–10,000) | Neutrophils (PMN) | ↓↓ (<45 mg/dL or <60% serum) | ↑↑ (>100 mg/dL) | Gram stain + culture. Empiric: ceftriaxone + vancomycin + dexamethasone ± ampicillin |
| Viral (Aseptic) | Normal or mildly ↑ | 10–500 (usually <300) | Lymphocytes | Normal (≥45) | Normal or mildly ↑ (<100) | Enteroviruses most common. HSV: lymphocytic pleocytosis + RBCs + temporal lobe changes. PCR diagnosis. |
| Fungal (Cryptococcus) | ↑↑↑ (often >300) | 5–100 (may be very low in immunosuppressed) | Lymphocytes | ↓ | ↑ | India ink positive (60–80%). Cryptococcal antigen (CSF + serum) >99% sensitivity. HIV + CD4 <100. |
| TB Meningitis | ↑ | 100–500 | Lymphocytes (early PMN possible) | ↓↓ (very low, can be <20) | ↑↑ (>100–500) | Basilar meningitis on MRI. AFB smear low sensitivity. ADA elevated. Treat empirically if suspected. |
| Lyme Meningitis | Normal or mildly ↑ | 10–200 | Lymphocytes | Normal | Mildly ↑ | Lymphocytic pleocytosis + Lyme serology (ELISA → Western blot). Treat with IV ceftriaxone × 14–28 days. |
| Type | Organism | Treatment | MRSA Coverage? |
|---|---|---|---|
| Non-purulent cellulitis (no pus, no abscess) | β-hemolytic Streptococci (Groups A, B, C, G) | Oral cephalexin or dicloxacillin × 5 days. IV if systemic toxicity, rapidly spreading, or immunocompromised. | NOT needed — not MRSA disease |
| Purulent cellulitis / Abscess | S. aureus (MRSA predominates in community) | I&D is definitive for abscess. Add TMP-SMX or doxycycline for moderate purulent cellulitis or abscess with systemic signs. | YES — CA-MRSA is the presumed organism |
| Severe cellulitis / SSTI with systemic toxicity | Polymicrobial, MRSA, or streptococcal | IV vancomycin (for MRSA) ± piperacillin-tazobactam (for polymicrobial). Hospital admission. | YES — empiric MRSA coverage required |
| Necrotizing Fasciitis | Type I: polymicrobial (Bacteroides + Streptococcus + coliforms). Type II: GAS alone (more aggressive). | IMMEDIATE surgical debridement + IV broad-spectrum antibiotics (pip-tazo + vancomycin ± clindamycin for toxin suppression) | SURGICAL EMERGENCY — mortality >30% if delayed |
| Organism | Presentation | Diagnosis | Treatment (CDC 2021) | Board Key |
|---|---|---|---|---|
| Neisseria gonorrhoeae | Purulent urethral/cervical discharge, dysuria. Men: purulent green/yellow discharge. Women: often asymptomatic. | NAAT (most sensitive). Gram stain: intracellular diplococci. | Ceftriaxone 500mg IM × 1 (1g if ≥150kg). MONOTHERAPY — no azithromycin added. | No fluoroquinolones (widespread resistance). Always test + treat for chlamydia co-infection if not excluded by NAAT. |
| Chlamydia trachomatis | Often asymptomatic (#1 reported STI in US). Mucopurulent discharge, dysuria, cervicitis, PID. | NAAT. | Doxycycline 100mg BID × 7 days (preferred over azithromycin — lower recurrence rate per 2021 update). | Doxycycline now preferred over azithromycin for chlamydia. Major CDC 2021 update boards test directly. |
| Non-gonococcal urethritis (NGU) | Mild discharge, dysuria, usually less purulent than GC | NAAT negative for GC/chlamydia. May be Mycoplasma genitalium, Ureaplasma. | Doxycycline 100mg BID × 7 days. | If recurrent/persistent NGU: test for Mycoplasma genitalium → treat with moxifloxacin if positive. |
| Trichomonas vaginalis | Women: frothy yellow-green vaginal discharge + "strawberry cervix" + pruritus. Men: often asymptomatic. | NAAT or wet prep (motile trichomonads). | Metronidazole 2g PO × 1 (or 500mg BID × 7d for recurrent). Treat BOTH partners simultaneously. | Concurrent treatment of sex partner is mandatory — very high re-infection rate without partner treatment. |
| Bacterial Vaginosis (BV) | Thin gray-white discharge + fishy odor (worse after sex). Clue cells on wet prep. Whiff test positive. | Amsel criteria (3 of 4) or Nugent score. | Metronidazole 500mg BID × 7 days OR vaginal metronidazole gel × 5 days. | BV is NOT an STI — it's a disruption of normal flora. Male partner treatment does NOT reduce recurrence (unlike trichomonas). |
| CD4 Count | OI Prophylaxis Threshold | Must-Consider Infections | Board Key |
|---|---|---|---|
| <500 | No specific prophylaxis; start ART | Bacterial pneumonia, TB reactivation, oral candidiasis, VZV reactivation | Start ART regardless of CD4 — U=U (undetectable = untransmittable) |
| <200 | PCP prophylaxis: TMP-SMX DS daily (/atovaquone/pentamidine) | Pneumocystis jirovecii (PCP) — bilateral GGO, dry cough, LDH elevated | PCP: TMP-SMX is treatment AND prophylaxis. Add prednisone if PaO₂ <70. |
| <100 | Toxoplasma prophylaxis: TMP-SMX DS covers both PCP and Toxo | Toxoplasmosis (multiple ring-enhancing lesions), Cryptococcal meningitis (India ink +, very high OP) | Single ring-enhancing lesion = lymphoma. Multiple = toxo. Empiric toxo treatment × 2 weeks; if no improvement → biopsy. |
| <50 | MAC prophylaxis: azithromycin weekly | CMV retinitis (floaters + visual loss + "pizza pie" fundus), MAC (fever + weight loss + night sweats + elevated ALP), Histoplasma | CMV retinitis: IV ganciclovir (or oral valganciclovir). Irreversible blindness if untreated — urgent ophthalmology. |
| Incubation | Mechanism | Organism | Key Feature | Treatment |
|---|---|---|---|---|
| 1–6 hours | Preformed toxin | S. aureus (staph toxin), B. cereus (emetic) | Rapid onset vomiting > diarrhea. Often after eating rice (B. cereus) or egg salad/deli meats (S. aureus). No fever. | Supportive only — toxin already formed, antibiotics useless |
| 8–16 hours | Preformed toxin | C. perfringens, B. cereus (diarrheal) | Diarrhea after beef stew, cafeteria food. Mild, self-limited <24h. | Supportive only |
| 1–3 days | Invasive / toxin-producing | Salmonella, Shigella, Campylobacter, ETEC, Vibrio | Fever + bloody diarrhea (Shigella, Campylobacter, Salmonella). ETEC = traveler's diarrhea (watery, no blood). Vibrio after raw oysters. | Shigella: azithromycin or fluoroquinolone. Campylobacter: azithromycin. Salmonella: usually self-limited; treat if immunocompromised or <3 months. |
| 3–5 days | Shiga toxin + invasive | STEC (E. coli O157:H7), EHEC | Bloody diarrhea + HUS (microangiopathic hemolytic anemia + thrombocytopenia + AKI). Children and elderly. | DO NOT give antibiotics — increases Shiga toxin release and HUS risk. Supportive care. No anti-motility agents. |
| Variable (post-antibiotic) | Toxin A+B mediated | C. difficile | Recent antibiotics + watery diarrhea ± pseudomembranes on colonoscopy. WBC >15K + Cr rise = severe. | Vancomycin PO or fidaxomicin. Stop offending antibiotic. Contact precautions. Soap and water (alcohol gel fails). |
| Antibiotic | Does NOT Cover | Board Trap Scenario |
|---|---|---|
| Cephalosporins (all generations) | Listeria monocytogenes, Enterococcus, MRSA (except ceftaroline) | Immunocompromised meningitis — add ampicillin for Listeria coverage |
| Nitrofurantoin | Systemic infection, pyelonephritis, bacteremia, Proteus, Klebsiella (variable) | Patient with pyelo started on nitrofurantoin — inadequate renal tissue levels |
| Azithromycin (macrolides) | MRSA, gram-negatives (except atypicals) | Gonorrhea treatment — azithromycin no longer recommended; ceftriaxone monotherapy per CDC 2021 |
| Metronidazole | Aerobic organisms, MRSA | Being added to aspiration pneumonia — increases mortality per IDSA 2019 without benefit |
| TMP-SMX | β-hemolytic Streptococci, Pseudomonas, Enterococcus | Non-purulent cellulitis — TMP-SMX targets MRSA but misses Strep; use cephalexin instead |
| Fluoroquinolones | MRSA (except some activity), Bacteroides, Enterococcus | Cipro for aspiration pneumonia — no anaerobic or atypical coverage in older formulations |
| Vancomycin | Gram-negative organisms, VRE (some strains), biofilm (needs higher levels) | VISA/VRSA: use linezolid or daptomycin |
| Antibiotic | Contraindicated In | Alternative |
|---|---|---|
| Doxycycline / Tetracyclines | Pregnancy (all trimesters), children <8 years | Azithromycin in pregnancy. Amoxicillin for Lyme in kids <8. Exception: no alternative for RMSF — doxycycline is used even in children <8 if RMSF suspected. |
| Fluoroquinolones | Children (theoretical cartilage damage), pregnancy (relative CI), myasthenia gravis (worsens NMJ block) | Beta-lactams for most pediatric/pregnancy infections. Avoid in MG. |
| Nitrofurantoin | Pyelonephritis, bacteremia, CrCl <30 (inadequate concentration), term pregnancy (>38 weeks — risk of neonatal hemolytic anemia) | Cephalexin or fosfomycin for UTI in pregnancy at term |
| Metronidazole | First trimester pregnancy (relative — teratogenicity concern); alcohol use during treatment | Topical metronidazole safer in first trimester. Avoid alcohol during and 48h after treatment. |
| Aminoglycosides | Pregnancy (ototoxicity/nephrotoxicity), CKD (nephrotoxic) | Use with caution, monitor levels. Avoid if possible in pregnancy. |